- Multivalent Peptide Vaccine,
- Peptide Cocktail Type,
- Personalized Peptide Vaccine,
- Peptide-Pulsed Dendritic Cancer Vaccine,
- Hybrid Peptide Vaccine,
- Others
Peptide Cancer Vaccine Market size was valued at USD 547.6 million in 2022, It is expected to reach a value of USD 1,501.5 million by 2029, growing at a CAGR of 15.5% from 2023 to 2029. The global market provides a detailed overview, which has been segmented by type, and application. The peptide cancer vaccine market has been segmented into Multivalent Peptide Vaccines, Peptide Cocktail Types, Personalized Peptide Vaccines, Peptide-Pulsed Dendritic Cancer Vaccines, Hybrid Peptide Vaccine, and Others. The peptide cocktail type segment is likely the most significant and fastest-growing in terms of type. Based on the application, the peptide cancer vaccine is segmented into Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, and Others. According to Precision Business Insights, the breast cancer segment is predicted to register the fastest growth rate during the forecast period.
Peptide Cancer Vaccine Market Key Development:
In December 2021, ISA pharmaceuticals presented key learnings in cancer vaccine development in an educational session at the ESMO Immune-Oncology Congress 2021.
Peptide Cancer Vaccine Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
15.5%
Largest Market
North America
Fastest Growing Market
Asia-Pacific
Peptide Cancer Vaccine Market Dynamics
The ability to quickly synthesize, prepare and use peptide vaccines, their use in clinical settings, and adaptability to changing antigens. Reduced risk of anaphylaxis caused by antigens are benefits that are anticipated to drive market growth for peptide cancer vaccines shortly.
North-America Got Significant Share
Peptide Cancer Vaccine Market Regional Analysis
The North American market is expected to witness the largest market share during the forecast period.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Peptide Cancer Vaccine Market Segmentation
By Type
By Application
- Breast Cancer,
- Lung Cancer,
- Melanoma,
- Prostate Cancer and
- Others
Frequently Asked Questions
The peptide cancer vaccine market size was valued at USD 547.6 million in 2022
The peptide cancer vaccine market key players are: Antigen Express BioLife Science Boston Biomedical Enzo Life Science Galena Biopharma Generex Biotechnology Generex Biotechnology Corporation Immatics Biotechnologies Immunomedics ISA Pharmaceuticals OncoTherapy Science Sellas TapImmune
The peptide cancer vaccine market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
| 1. Executive Summary |
| 2. Global Peptide Cancer Vaccine Market Introduction |
| 2.1. Global Peptide Cancer Vaccine Market Taxonomy |
| 2.2. Global Peptide Cancer Vaccine Market Definitions |
| 2.2.1. By Type |
| 2.2.2. By Application |
| 2.2.3. By Region |
| 3. Global Peptide Cancer Vaccine Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Peptide Cancer Vaccine Market Dynamic Factors - Impact Analysis |
| 3.6. Global Peptide Cancer Vaccine Market Competition Landscape |
| 4. Global Peptide Cancer Vaccine Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Peptide Cancer Vaccine Market, By Type, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1. Multivalent Peptide Vaccine |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Peptide Cocktail Types |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Personalized Peptide Vaccine |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Peptide-Pulsed Dendritic Cancer Vaccine |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Hybrid Peptide Vaccine |
| 5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Others |
| 5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 6. Global Peptide Cancer Vaccine Market, By Application, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1. Breast Cancer |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Lung Cancer |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Melanoma |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Prostate Cancer |
| 6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Others |
| 6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7. Global Peptide Cancer Vaccine Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia-Pacific |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Latin America |
| 7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Middle East and Africa |
| 7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Global Peptide Cancer Vaccine Market - Opportunity Analysis Index, By Type, Application, and Region, 2023 - 2029 |
| 8. North America Peptide Cancer Vaccine Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.1. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1. Multivalent Peptide Vaccine |
| 8.1.2. Peptide Cocktail Type |
| 8.1.3. Personalized Peptide Vaccine |
| 8.1.4. Peptide-Pulsed Dendritic Cancer Vaccine |
| 8.1.5. Hybrid Peptide Vaccine |
| 8.1.6. Others |
| 8.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1. Breast Cancer |
| 8.2.2. Lung Cancer |
| 8.2.3. Melanoma |
| 8.2.4. Prostate Cancer |
| 8.2.5. Others |
| 8.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 8.3.1. USA |
| 8.3.2. Canada |
| 8.4. North America Peptide Cancer Vaccine Market - Opportunity Analysis Index, By Type, Application, and Country, 2023 - 2029 |
| 8.5. North America Peptide Cancer Vaccine Market Dynamics Trends |
| 9. Europe Peptide Cancer Vaccine Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 9.1. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Multivalent Peptide Vaccine |
| 9.1.2. Peptide Cocktail Type |
| 9.1.3. Personalized Peptide Vaccine |
| 9.1.4. Peptide-Pulsed Dendritic Cancer Vaccine |
| 9.1.5. Hybrid Peptide Vaccine |
| 9.1.6. Others |
| 9.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1. Breast Cancer |
| 9.2.2. Lung Cancer |
| 9.2.3. Melanoma |
| 9.2.4. Prostate Cancer |
| 9.2.5. Others |
| 9.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.3.1. Germany |
| 9.3.2. UK |
| 9.3.3. France |
| 9.3.4. Spain |
| 9.3.5. Italy |
| 9.3.6. Russia |
| 9.3.7. Rest of Europe |
| 9.4. Europe Peptide Cancer Vaccine Market - Opportunity Analysis Index, By Type, Application, and Country, 2023 - 2029 |
| 9.5. Europe Peptide Cancer Vaccine Market Dynamics Trends |
| 10. Asia-Pacific Peptide Cancer Vaccine Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 10.1. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Multivalent Peptide Vaccine |
| 10.1.2. Peptide Cocktail Type |
| 10.1.3. Personalized Peptide Vaccine |
| 10.1.4. Peptide-Pulsed Dendritic Cancer Vaccine |
| 10.1.5. Hybrid Peptide Vaccine |
| 10.1.6. Others |
| 10.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Breast Cancer |
| 10.2.2. Lung Cancer |
| 10.2.3. Melanoma |
| 10.2.4. Prostate Cancer |
| 10.2.5. Others |
| 10.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. China |
| 10.3.2. India |
| 10.3.3. Japan |
| 10.3.4. ASEAN |
| 10.3.5. Australia & New Zealand |
| 10.3.6. Rest of Asia-Pacific |
| 10.4. Asia-Pacific Peptide Cancer Vaccine Market - Opportunity Analysis Index, By Type, Application, and Country, 2023 - 2029 |
| 10.5. Asia-Pacific Peptide Cancer Vaccine Market Dynamics Trends |
| 11. Latin America Peptide Cancer Vaccine Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 11.1. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Multivalent Peptide Vaccine |
| 11.1.2. Peptide Cocktail Type |
| 11.1.3. Personalized Peptide Vaccine |
| 11.1.4. Peptide-Pulsed Dendritic Cancer Vaccine |
| 11.1.5. Hybrid Peptide Vaccine |
| 11.1.6. Others |
| 11.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Breast Cancer |
| 11.2.2. Lung Cancer |
| 11.2.3. Melanoma |
| 11.2.4. Prostate Cancer |
| 11.2.5. Others |
| 11.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Brazil |
| 11.3.2. Mexico |
| 11.3.3. Argentina |
| 11.3.4. Rest of Latin America |
| 11.4. Latin America Peptide Cancer Vaccine Market - Opportunity Analysis Index, By Type, Application, and Country, 2023 - 2029 |
| 11.5. Latin America Peptide Cancer Vaccine Market Dynamics Trends |
| 12. Middle East and Africa Peptide Cancer Vaccine Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 12.1. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Multivalent Peptide Vaccine |
| 12.1.2. Peptide Cocktail Type |
| 12.1.3. Personalized Peptide Vaccine |
| 12.1.4. Peptide-Pulsed Dendritic Cancer Vaccine |
| 12.1.5. Hybrid Peptide Vaccine |
| 12.1.6. Others |
| 12.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Breast Cancer |
| 12.2.2. Lung Cancer |
| 12.2.3. Melanoma |
| 12.2.4. Prostate Cancer |
| 12.2.5. Others |
| 12.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Gulf Cooperation Council (GCC) Countries |
| 12.3.2. Israel |
| 12.3.3. South Africa |
| 12.3.4. Rest of MEA |
| 12.4. MEA Peptide Cancer Vaccine Market - Opportunity Analysis Index, By Type, Application, and Country, 2023 - 2029 |
| 12.5. MEA Peptide Cancer Vaccine Market Dynamics Trends |
| 13. Competition Landscape |
| 13.1. Strategic Dashboard of Top Market Players |
| 13.2. Company Profiles (Introduction, Financial Analysis, Type Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 13.2.1. Antigen Express |
| 13.2.2. BioLife Science |
| 13.2.3. Boston Biomedical |
| 13.2.4. Enzo Life Science |
| 13.2.5. Galena Biopharma |
| 13.2.6. Generex Biotechnology |
| 13.2.7. Generex Biotechnology Corporation |
| 13.2.8. Immatics Biotechnologies |
| 13.2.9. Immunomedics |
| 13.2.10. ISA Pharmaceuticals |
| 13.2.11. OncoTherapy Science |
| 13.2.12. Sellas |
| 13.2.13. TapImmune |
| 13.2.14. VAXON Biotech |
| 14. Research Methodology |
| 15. Key Assumptions and Acronyms |
- Antigen Express
- BioLife Science
- Boston Biomedical
- Enzo Life Science
- Galena Biopharma
- Generex Biotechnology
- Generex Biotechnology Corporation
- Immatics Biotechnologies
- Immunomedics
- ISA Pharmaceuticals
- OncoTherapy Science
- Sellas
- TapImmune